TrialHuman vaccines & immunotherapeutics2014

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Mark H Einstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.